Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $206,222.04 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Lin Wei sold 2,073 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $206,222.04. Following the completion of the transaction, the insider owned 101,366 shares in the company, valued at $10,083,889.68. The trade was a 2.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Revolution Medicines Trading Down 3.5%

Shares of Revolution Medicines stock opened at $95.78 on Friday. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16. Revolution Medicines, Inc. has a 12-month low of $29.17 and a 12-month high of $124.49. The company has a market capitalization of $18.98 billion, a price-to-earnings ratio of -16.21 and a beta of 0.99. The firm’s 50-day moving average price is $102.96 and its two-hundred day moving average price is $77.07.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same quarter in the prior year, the business posted ($1.12) EPS. On average, analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on RVMD shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Jefferies Financial Group assumed coverage on Revolution Medicines in a report on Monday, March 16th. They set a “buy” rating for the company. UBS Group began coverage on Revolution Medicines in a research note on Friday, February 27th. They issued a “buy” rating on the stock. Wedbush reiterated an “outperform” rating on shares of Revolution Medicines in a research report on Friday, January 9th. Finally, Evercore raised Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, February 25th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $78.94.

Key Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Large institutional interest — several big funds (General Atlantic, Norges Bank, Avoro, UBS, Polar Capital) have taken or increased stakes recently, which signals strong institutional conviction and can provide buying support. MarketBeat Institutional/Insider Summary
• Positive Sentiment: Analyst tone is largely favorable — multiple upgrades/initiations and a consensus “Buy” bias underpin positive sentiment among investors and can stabilize demand. Analyst Coverage Summary
• Neutral Sentiment: Company profile and pipeline are long-term positives but carry standard biotech clinical/readout risk — lead programs include RMC‑4630 (SHP2), RMC‑6291 (KRAS G12C) and RMC‑6236 (pan‑RAS).
• Neutral Sentiment: Recent results (Feb. 25) showed a wider-than-expected quarterly loss (EPS -$1.86 vs. -$1.56 est.), a reminder of ongoing cash burn and negative EPS guidance for the year — a typical headwind for development-stage biotechs. Earnings Summary
• Negative Sentiment: Unusual options activity — investors bought 12,797 put contracts (a ~131% increase vs. average put volume of 5,546), a bearish flow that can amplify near‑term downside and volatility.
• Negative Sentiment: Cluster of insider sales on Mar. 17 — several senior insiders trimmed positions (Mark A. Goldsmith 12,871 shares; Margaret A. Horn 4,583; Stephen M. Kelsey 4,302; Jack Anders 2,753; Lin Wei 2,073; Xiaolin Wang 2,010). Multiple Form 4 filings were submitted to the SEC, which can be interpreted negatively by some investors even if sales are for diversification or routine reasons. SEC filings: Read More. · Read More. · Read More. · Read More. · Read More. · Read More.

Institutional Investors Weigh In On Revolution Medicines

Several hedge funds have recently added to or reduced their stakes in the business. General Atlantic L.P. bought a new stake in Revolution Medicines during the 3rd quarter worth approximately $115,556,000. Norges Bank acquired a new position in Revolution Medicines in the 4th quarter valued at approximately $195,568,000. Avoro Capital Advisors LLC bought a new position in shares of Revolution Medicines during the fourth quarter valued at $172,840,000. UBS Group AG raised its stake in shares of Revolution Medicines by 183.6% during the fourth quarter. UBS Group AG now owns 3,087,937 shares of the company’s stock valued at $245,954,000 after acquiring an additional 1,998,972 shares during the last quarter. Finally, Polar Capital Holdings Plc lifted its holdings in shares of Revolution Medicines by 321.2% during the fourth quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company’s stock worth $160,398,000 after purchasing an additional 1,535,686 shares during the period. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.